Literature DB >> 16247754

Intense paraneoplastic neutrophilic leukemoid reaction related to a G-CSF-secreting lung sarcoma.

Fabrice Jardin1, Marc Vasse, Marc Debled, Stéphane Dominique, Philippe Courville, Françoise Callonnec, Gérard Buchonnet, Luc Thiberville, Hervé Tilly.   

Abstract

A white blood cell count more than 50 x 10(9)/l, not related to bone marrow involvement, is termed leukemoid reaction. We report on the first case of an undifferentiated sarcoma of the lung associated with an intense paraneoplastic neutrophilic leukemoid reaction related to the production of granulocyte colony-stimulating factor (G-CSF). A radiography and a computed tomography scan of the chest revealed a well-limited voluminous and heterogeneous low-density mass of the left lung. The patient died of multiorgan failure related to uncontrolled progressive tumor growth after admission and two cycles of chemotherapy. The patient's G-CSF serum concentration was dramatically elevated (6,538 pg/ml) compared to serum levels observed in normal controls and patients with elevated leukocytosis (31 and 387 pg/ml, respectively). The G-CSF concentration dramatically increased after the first cycle of chemotherapy and during the subsequent neutropenia, as a result of the tumor lyses as well as of disruption of the physiological negative feedback mechanism. Adjunction of the patient's serum to CD34+ cell cultures induced a 12.3-fold increase in CD15+ cells, demonstrating the serum's capacity to induce myeloid differentiation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16247754     DOI: 10.1002/ajh.20454

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  15 in total

Review 1.  Paraneoplastic granulocytosis in metastatic melanoma.

Authors:  Jeremy L Davis; R Taylor Ripley; Timothy L Frankel; Irina Maric; Jay N Lozier; Steven A Rosenberg
Journal:  Melanoma Res       Date:  2010-08       Impact factor: 3.599

2.  Paraneoplastic leukemoid reaction in pancreatic cancer: A case report.

Authors:  Mélanie Dos Santos; Karine Bouhier; Manh-Thong Dao
Journal:  World J Gastrointest Oncol       Date:  2015-10-15

3.  A case of leukemoid reaction in a patient with sarcomatous hepatocellular carcinoma.

Authors:  Hyun Phil Shin; Jung Won Jeon; Jae Jun Park; Jae Myung Cha; Kwang Ro Joo; Joung Il Lee; Gou Young Kim; So Young Kang
Journal:  Korean J Hepatol       Date:  2011-09

4.  Paraneoplastic leukemoid reaction in a patient with BRAF V600E-mutated metastatic malignant melanoma.

Authors:  Emanuel Gouveia; Mónica Sousa; Maria José Passos; António Moreira
Journal:  BMJ Case Rep       Date:  2015-01-09

5.  Melanoma induced immunosuppression is mediated by hematopoietic dysregulation.

Authors:  Neha Kamran; Youping Li; Maria Sierra; Mahmoud S Alghamri; Padma Kadiyala; Henry D Appelman; Marta Edwards; Pedro R Lowenstein; Maria G Castro
Journal:  Oncoimmunology       Date:  2017-12-14       Impact factor: 8.110

6.  A G-CSF-secreting adrenal carcinoma with rhabdoid-like differentiation causing leukocytosis.

Authors:  Emil Lou; Jeremy Goodwin; David N Howell; John Hicks; L Brett Caram
Journal:  Nat Rev Urol       Date:  2009-07       Impact factor: 14.432

Review 7.  Chronic neutrophilic leukemia: new science and new diagnostic criteria.

Authors:  Natasha Szuber; Ayalew Tefferi
Journal:  Blood Cancer J       Date:  2018-02-13       Impact factor: 11.037

8.  A Paraneoplastic Leukemoid Reaction in Primary Lung Sarcoma.

Authors:  Ali F Al Sbihi; Nouraldeen Manasrah; Farah M Al Haj; Sarah Al Qasem; Joel Appel
Journal:  Cureus       Date:  2021-05-15

9.  Inflammatory malignant fibrous histiocytoma associated with leukemoid reaction or leukocytosis: a comprehensive review.

Authors:  Jorge Hurtado-Cordovi; Prajwol Pathak; Boris Avezbakiyev; Marianne Frieri
Journal:  ISRN Oncol       Date:  2012-10-14

Review 10.  A role for G-CSF and GM-CSF in nonmyeloid cancers.

Authors:  Alexander M Aliper; Victoria P Frieden-Korovkina; Anton Buzdin; Sergey A Roumiantsev; Alex Zhavoronkov
Journal:  Cancer Med       Date:  2014-04-02       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.